75 related articles for article (PubMed ID: 11303598)
1. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity.
Pendyala L; Schwartz G; Bolanowska-Higdon W; Hitt S; Zdanowicz J; Murphy M; Lawrence D; Creaven PJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):269-72. PubMed ID: 11303598
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial.
Pendyala L; Creaven PJ
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):245-51. PubMed ID: 7606199
[TBL] [Abstract][Full Text] [Related]
3. Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
Benson AB; Olopade OI; Ratain MJ; Rademaker A; Mobarhan S; Stucky-Marshall L; French S; Dolan ME
Clin Cancer Res; 2000 Oct; 6(10):3870-7. PubMed ID: 11051232
[TBL] [Abstract][Full Text] [Related]
4. Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.
Kensler TW; He X; Otieno M; Egner PA; Jacobson LP; Chen B; Wang JS; Zhu YR; Zhang BC; Wang JB; Wu Y; Zhang QN; Qian GS; Kuang SY; Fang X; Li YF; Yu LY; Prochaska HJ; Davidson NE; Gordon GB; Gorman MB; Zarba A; Enger C; Muñoz A; Helzlsouer KJ
Cancer Epidemiol Biomarkers Prev; 1998 Feb; 7(2):127-34. PubMed ID: 9488587
[TBL] [Abstract][Full Text] [Related]
5. Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage.
Arfsten DP; Johnson EW; Wilfong ER; Jung AE; Bobb AJ
Cutan Ocul Toxicol; 2007; 26(2):113-34. PubMed ID: 17612979
[TBL] [Abstract][Full Text] [Related]
6. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology.
Arfsten D; Johnson E; Thitoff A; Jung A; Wilfong E; Lohrke S; Bausman T; Eggers J; Bobb A
Int J Toxicol; 2004; 23(4):239-47. PubMed ID: 15371168
[TBL] [Abstract][Full Text] [Related]
7. Smokers and urinary genotoxins: implications for selection of cohorts and modulation of endpoints in chemoprevention trials.
De Flora S; Camoirano A; Bagnasco M; Bennicelli C; van Zandwijk N; Wigbout G; Qian GS; Zhu YR; Kensler TW
J Cell Biochem Suppl; 1996; 25():92-8. PubMed ID: 9027604
[TBL] [Abstract][Full Text] [Related]
8. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
Jacobson LP; Zhang BC; Zhu YR; Wang JB; Wu Y; Zhang QN; Yu LY; Qian GS; Kuang SY; Li YF; Fang X; Zarba A; Chen B; Enger C; Davidson NE; Gorman MB; Gordon GB; Prochaska HJ; Egner PA; Groopman JD; Muñoz A; Helzlsouer KJ; Kensler TW
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):257-65. PubMed ID: 9107431
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
10. Chronic dosing of oltipraz in people at increased risk for colorectal cancer.
Szarka CE; Yao KS; Pfeiffer GR; Balshem AM; Litwin S; Frucht H; Goosenberg EB; Engstrom PF; Clapper ML; O'Dwyer PJ
Cancer Detect Prev; 2001; 25(4):352-61. PubMed ID: 11531012
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
Gupta E; Olopade OI; Ratain MJ; Mick R; Baker TM; Berezin FK; Benson AB; Dolan ME
Clin Cancer Res; 1995 Oct; 1(10):1133-8. PubMed ID: 9815904
[TBL] [Abstract][Full Text] [Related]
12. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies.
Dimitrov NV; Leece CM; Tompkins ER; Seymour E; Bennink M; Gardiner J; Crowell J; Hawk E; Nashawaty M; Bennett JL
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):201-7. PubMed ID: 11303588
[TBL] [Abstract][Full Text] [Related]
13. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
14. NTP technical report on the toxicity studies of Riddelliine (CAS No. 23246-96-0) Administered by Gavage to F344 Rats and B6C3F1 Mice.
Chan P
Toxic Rep Ser; 1993 Dec; 27():1-D9. PubMed ID: 12209179
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
16. Tetracycline-induced reproductive toxicity in male rats: effects of vitamin C and N-acetylcysteine.
Farombi EO; Ugwuezunmba MC; Ezenwadu TT; Oyeyemi MO; Ekor M
Exp Toxicol Pathol; 2008 Jun; 60(1):77-85. PubMed ID: 18406588
[TBL] [Abstract][Full Text] [Related]
17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Oxymetholone (CAS NO. 434-07-1) in F344/N Rats and Toxicology Studies of Oxymetholone in B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Aug; 485():1-233. PubMed ID: 12571678
[TBL] [Abstract][Full Text] [Related]
20. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
